Your fact-checks will appear here
Organization
Salvage radiotherapy (sRT) planning should synthesize PSA kinetics (especially PSA doubling time), PSMA-PET findings, pathologic Gleason Grade Group, and margin status to stratify risk, decide on targ...
Salvage radiotherapy (SRT) works best when PSA is low: multiple guideline reviews and cohort studies show improved biochemical-relapse–free and metastasis-free survival when SRT is given at lower PSA ...
Guidelines and large studies do not set a single PSA “trigger” after radical prostatectomy; contemporary recommendations commonly consider salvage radiation once PSA is detectable and rising, with thr...
After radical prostatectomy (RP), the American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology (AUA/ASTRO/SUO) 2024–25 guidance advises offering salvage rad...
PSA doubling time (PSADT) and PSA velocity (PSAV) are established prognostic markers used to time salvage therapy: short PSADT — commonly <6–12 months — signals higher risk of metastasis and is cited ...
Current expert guidance recommends next‑generation molecular PET—preferably PSMA‑PET—plus pelvic MRI when evaluating suspected recurrence before offering curative‑intent salvage radiation therapy; gui...
Salvage radiotherapy (SRT) is the primary potentially curative option for biochemical recurrence after radical prostatectomy and is often recommended early when PSA is low; randomized trials (GETUG‑AF...
Guidance and studies converge on one principle: earlier salvage radiotherapy (SRT) after radical prostatectomy—when PSA is low—is associated with better biochemical control, metastasis‑free outcomes a...
Early initiation of salvage radiotherapy (SRT) at low prostate‑specific antigen (PSA) levels is consistently associated with better long‑term oncologic control—studies and guidelines report improved b...
Salvage radiation therapy (SRT) is the primary curative local option for men with biochemical recurrence (BCR) after radical prostatectomy; guidelines define BCR as PSA ≥0.2 ng/mL confirmed and recomm...